about
Rates and equilibria for probe capture by an antibody with infinite affinity.In Vivo Pretargeted Imaging of HER2 and TAG-72 Expression Using the HaloTag Enzyme.Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imagingPreparation of (111)In-DTPA morpholino oligomer for low abdominal accumulation.Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complexAdding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted.A preclinical 188Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49.90Y labeled phosphorodiamidate morpholino oligomer for pretargeting radiotherapy.A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to RituximabPretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibodyTheranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.Intraperitoneal injection is not always a suitable alternative to intravenous injection for radiotherapySelf-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.The ratio of maximum percent tumour accumulations of the pretargeting agent and the radiolabelled effector is independent of tumour size.Receptor-mediated tumor targeting with radiopeptides. Part 1. General principles and methods.Pretargeted molecular imaging and radioimmunotherapy.Bioorthogonal chemistry: implications for pretargeted nuclear (PET/SPECT) imaging and therapy.New insights into the pretargeting approach to image and treat tumours.Use of Morpholino Oligomers for Pretargeting.
P2860
Q33821333-3207C524-C53B-4B24-83D5-B42861CCBA0EQ33877207-BDEB9CD1-7FD8-4DF8-A598-BE9B2CB185BFQ33921086-A86DAC24-5136-4CD5-9CC0-9724E4833961Q34014474-0233AE3E-87C4-4647-840F-0D8972AE64BFQ34456470-D8436E84-02A8-4D30-9AE3-C77B038E14EDQ34519414-332B6F33-07EE-49F1-B1F5-5A8644693286Q34979175-0EC3525A-B9C1-42AF-B128-82EBF424908DQ35629379-C8D54044-4F5A-4EB8-8754-25D1149B80E3Q35633346-BBD5E132-AFF2-4D34-B5D7-620A1676A63CQ35991899-72902E4E-5253-45BE-B364-A84C5D490775Q36746466-CFBA3B91-9B52-4212-BAA9-06DDBD5F6DA5Q36842135-8D3D4411-6BF0-418E-80EB-3BECEC165210Q37233043-90A35C52-E6E0-422A-B327-2280EEB16885Q37373494-5CC83C54-0119-4A8A-95C0-0389974DA957Q37481714-A7D2AA31-313A-4649-A1D7-C82046293006Q37515337-5928ED01-D4B2-4CF0-9854-3379F64EAE72Q38022016-3A45D01F-55F0-4448-AA8D-21C7A43584C4Q38206206-222A9A0B-201C-4F90-ABAA-CA5A4C97A3B5Q38976879-DB7CB4B2-A5D3-4BBE-AAC1-5BF75DD2EFFBQ50665399-FE08895F-9176-4B5B-8B09-E1CE3533F5A5
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
A semiempirical model of tumor pretargeting.
@en
A semiempirical model of tumor pretargeting.
@nl
type
label
A semiempirical model of tumor pretargeting.
@en
A semiempirical model of tumor pretargeting.
@nl
prefLabel
A semiempirical model of tumor pretargeting.
@en
A semiempirical model of tumor pretargeting.
@nl
P2860
P356
P1476
A semiempirical model of tumor pretargeting.
@en
P2093
Donald J Hnatowich
Guozheng Liu
P2860
P304
P356
10.1021/BC8002748
P577
2008-11-01T00:00:00Z